Jublia Access Challenges: What Providers and Prescribers Need to Know in 2026

Jublia (efinaconazole 10% topical solution) is not in an FDA-listed drug shortage as of 2026. However, many prescribers are experiencing increased friction at the point of prescribing — patients returning with unfilled prescriptions due to cost, insurance denials, and pharmacy access limitations. This guide summarizes the key barriers and offers clinical strategies to help your patients get the treatment they need.

Current Jublia Supply Status (2026)

Jublia is manufactured by Ortho Dermatologics (Bausch Health) and remains commercially available. The medication is not on the FDA's drug shortage list. Supply chain issues are not the source of patient access problems.

The key driver of access problems is a combination of high branded drug pricing, formulary exclusions, and step therapy requirements that affect a large proportion of commercially insured and Medicare patients. Understanding these barriers will help you set realistic expectations with patients and prepare them for what to expect when filling this prescription.

Key Prescribing Facts: Jublia at a Glance

Drug class: Triazole antifungal (azole); 14α-demethylase inhibitor

Indication: Toenail onychomycosis due to T. rubrum and T. mentagrophytes

Age: FDA-approved for patients 6 years and older (2020 label expansion)

Dosing: Apply once daily for 48 weeks using the integrated flow-through brush applicator

Efficacy: Complete cure rate 17.8% (Trial 1) and 15.2% (Trial 2) vs. 3.3% and 5.5% vehicle; mycologic cure approximately 55% in both trials

Controlled substance: No — no DEA scheduling requirements

Drug interactions: No known clinically significant drug interactions (minimal systemic absorption)

Understanding the Insurance Barriers Your Patients Face

Jublia faces several formulary challenges across insurance classes:

Commercial insurance: Coverage varies widely. Many plans place Jublia on Tier 3 or higher, or require prior authorization. Step therapy requiring documented failure of terbinafine or ciclopirox is common.

Medicare Part D: Most Medicare Part D plans do not cover Jublia. It is often excluded from formulary entirely. Patients on Medicare are also ineligible for the manufacturer Rx Access Program.

Medicaid: Coverage varies by state. Some state Medicaid programs cover Jublia with prior authorization; others do not cover it at all.

Tips for Navigating Prior Authorization

When submitting a prior authorization for Jublia, strengthen your request by including:

Confirmed mycological diagnosis (KOH prep or culture, PAS stain, or PCR results)

Clinical documentation of why oral terbinafine is contraindicated or not tolerated (hepatic disease, drug interactions, patient refusal due to systemic side effects, prior treatment failure)

Documentation of any previous treatments tried and failed (ciclopirox, OTC antifungals)

Clear clinical rationale for topical over oral therapy (comorbidities, polypharmacy, patient preference with shared decision-making)

Clinical Alternatives to Consider When Jublia Is Inaccessible

AAFP and AAD guidelines note that oral terbinafine is the preferred first-line treatment for toenail onychomycosis due to superior efficacy (complete cure ~38%) and tolerability for most patients. When prescribing terbinafine, be aware of key interactions with tricyclic antidepressants, SSRIs, beta-blockers, atypical antipsychotics, and tamoxifen.

For patients who cannot take oral antifungals, generic ciclopirox nail lacquer (8%) is the most affordable topical alternative. Generic tavaborole (boron-based antifungal) is now FDA-approved and may be available at lower cost than brand Jublia, with similar clinical cure rates (~15%).

Savings Programs Worth Sharing with Your Patients

If your patient needs Jublia and you want to maximize their chance of accessing it, share these resources at the point of care:

Ortho Dermatologics Rx Access Program (OrthoRxAccess.com): Commercially insured patients may pay $0; cash-pay patients pay $75/4mL bottle. Valid at Walgreens and participating independent pharmacies only. Not valid for Medicare/Medicaid.

Bausch Health Patient Assistance Program: Income-based program for uninsured patients. Contact the program directly for eligibility criteria and enrollment.

GoodRx / SingleCare discount coupons: Reduce cash price to ~$727–$741 per 4 mL bottle at most chain pharmacies.

How medfinder Supports Your Patients

medfinder is a service that calls pharmacies on behalf of your patients to identify which ones can fill their prescription. This is particularly valuable for a medication like Jublia where pharmacy program access and stocking can vary significantly by location. Learn how to help your patients find Jublia in stock with our provider guide.